Brief: Ascletis Announces Positive Topline Results from U.S. Phase II for Its Ultra-Long-Acting GLP-1R Agonist ASC30 for Obesity
10/03/2026 10:06
March 10 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE II, 24-WEEK STUDY FOR ITS ULTRA-LONG-ACTING SUBCUTANEOUS DEPOT FORMULATIONS OF SMALL MOLECULE GLP-1R AGONIST ASC30 FOR OBESITY ASCLETIS PHARMA INC - ASC30 ACHIEVES 7.5% PLACEBO-ADJUSTED MEAN WEIGHT LOSS AT WEEK 16 AFTER THREE MONTHLY DOSES ASCLETIS PHARMA INC - ASC30 DEMONSTRATES SAFETY PROFILE CONSISTENT WITH GLP-1 DRUG CLASS ASCLETIS PHARMA INC - ASC30 MAINTAINS WEIGHT LOSS FOR FOUR MONTHS AFTER FINAL MONTHLY DOSE ASCLETIS PHARMA INC - NO DISCONTINUATIONS DUE TO ADVERSE EVENTS FOR ASC30 OR PLACEBO ASCLETIS PHARMA INC: ASC30 PHASE II STUDY ACHIEVED ITS PRIMARY ENDPOINT Source text: ID:nPn4ZwWQ3a Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026